Psychiatric disorders in myasthenia gravis;Transtornos psiquiátricos na miastenia gravis

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 2 A, 2011, Pages 176-179

  Ybarra, Mariana Inés ^a   Kummer, Arthur ^a   Frota, Elizabeth Regina Comini ^a   de Oliveira, José Teotônio ^a   Gomez, Rodrigo Santiago ^a   Teixeira, Antonio Lucio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Depression; Mental health; Myasthenia gravis; Neuropsychiatry

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DEPRESSION; DISEASE DURATION; DYSTHYMIA; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MYASTHENIA GRAVIS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; SOCIAL PHOBIA; STRUCTURED INTERVIEW; SUICIDAL IDEATION;

EID: 79955804796     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000200006     Document Type: Article

References (23)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-490.
2. Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci 1999;170: 77-89.
3. Hoefer PF, Aranow H Jr., Rowland L P. Myasthenia gravis and epilepsy. AMA Arch Neurol Psychiatry 1958;80:10-17.
4. Hokkanen E, Toivakka E. Electroencephalographic findings in myasthenia gravis: 180 EEG recordings of 109 patients. Acta Neurol Scand 1969;45:556-567.
5. Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI. Memory dysfunction in myasthenia gravis: evidence for central cholinergic effects. Neurology 1988;38:1173-1177.
6. Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology 1976;26:311-316.
7. Sitek EJ, Bilinska MM, Wieczorek D, Nyka WM. Neuropsychological assessment in myasthenia gravis. Neurol Sci 2009;30:9-14.
8. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin 2006; 24:441-460.
9. Kulaksizoglu I. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007;21:473-481.
10. nd Ed. New York: Humana Press, 2009.
11. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsy-chiatric Interview: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33.
12. Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988;77:443-445.
13. Paradis CM, Friedman S, Lazar RM, Kula RW. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry 1993;150:1102-1104.
14. th European Congress on Traumatic Stress 1999:147-148.
15. Bartel PR, Lotz BP. Neuropsychological test performance and affect in myasthenia gravis. Acta Neurol Scand 1995;91:266-270.
16. Lundeen J, Fisher J, Kothari MJ. Frequency of anxiety in myasthenia gravis. J Clin Neuromuscul Dis 2004;6:9-12.
17. Paul RH, Cohen RA, Goldstein JM, Gilchrist JM. Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000;12:499-501.
18. Stewart SB, Robertson KR, Johnson KM, Howard JF. The prevalence of depression in myasthenia gravis. J Clin Neuromuscul Dis 2007;8:111-115.
19. Doering S, Henze T, Schussler G. Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 1993;50:617-620.
20. Patten SB. Exogenous corticosteroids and major depression in the general population. J Psychosom Res 2000;49:447-449.
21. Pretorius E. Corticosteroids, depression and the role of serotonin. Rev Neurosci 2004;15:109-116.
22. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
23. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001;24: 512-516.